[HTML] springer.com

[HTML][HTML] Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small …

CH Chiu, MC Lin, YF Wei, GC Chang, WC Su… - Targeted Oncology, 2023 - Springer
Background In RELAY, a randomized, double-blind, phase III trial investigating the efficacy
and safety of ramucirumab+ erlotinib (RAM+ ERL) or ERL+ placebo (PBO) in patients with …
被引用次数：2 相关文章
[HTML] nih.gov

[HTML][HTML] Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small …

CH Chiu, MC Lin, YF Wei, GC Chang, WC Su… - Targeted …, 2023 - ncbi.nlm.nih.gov
Background In RELAY, a randomized, double-blind, phase III trial investigating the efficacy
and safety of ramucirumab+ erlotinib (RAM+ ERL) or ERL+ placebo (PBO) in patients with …

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell …

CH Chiu, MC Lin, YF Wei, GC Chang, WC Su… - Targeted …, 2023 - europepmc.org
Background In RELAY, a randomized, double-blind, phase III trial investigating the efficacy
and safety of ramucirumab+ erlotinib (RAM+ ERL) or ERL+ placebo (PBO) in patients with …

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell …

CH Chiu, MC Lin, YF Wei, GC Chang… - Targeted …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In RELAY, a randomized, double-blind, phase III trial investigating the efficacy
and safety of ramucirumab+ erlotinib (RAM+ ERL) or ERL+ placebo (PBO) in patients with …